Cagrilintide

Clinical Trials

Cagrilintide

Aliases
CagriSema (combo with semaglutide)
Administration
Subcutaneous injection (once weekly)

Documented benefits

Tier 1 · Peer-reviewed / regulatory

Weight Loss & Metabolism

Cagrilintide's defining research application — the only amylin-mimicking peptide in this database, distinct from GLP-1 drugs.

Appetite suppression

Adds a second, independent layer of appetite suppression by mimicking amylin rather than GLP-1.

Weight loss

Produces additive weight loss when combined with a GLP-1 drug, via a completely separate hormone pathway.

Blood sugar regulation

Amylin's natural role in slowing gastric emptying contributes to steadier post-meal blood sugar.